ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer

DISEASE CHARACTERISTICS:

* Histologically confirmed malignancy, meeting 1 of the following criteria:

  * Solid tumor that is refractory to ≥ 1 line of standard treatment OR for which no standard therapy is available

    * Must have ≥ 1 lesion amenable to percutaneous biopsy (for solid tumor patients enrolled after the initial phase of the study)
  * Chronic lymphocytic leukemia (CLL) or follicular lymphoma with no current indication for standard therapy OR disease that has failed ≥ 1 line of standard therapy
* No disease-associated symptoms requiring immediate therapy or other interventions
* Must be willing to undergo tumor biopsies\* after the initial phase of the study NOTE: \*Patients with CLL undergo peripheral blood collection instead of biopsy
* No primary brain tumors, brain metastases, or leptomeningeal disease

PATIENT CHARACTERISTICS:

* ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
* Life expectancy ≥ 3 months
* Absolute neutrophil count ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Hemoglobin ≥ 9 g/dL
* Bilirubin \< 1.5 times upper limit of normal (ULN)
* AST and ALT ≤ 2.5 times ULN
* Creatinine \< 1.5 times ULN OR creatinine clearance ≥ 60 mL/min
* INR ≤ 1.4
* PTT ≤ 36 seconds
* Calcium (corrected) normal
* Magnesium \< 1.5 times ULN
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 30 days after study completion
* No history of seizures
* No evidence of bleeding diathesis
* No uncontrolled intercurrent illness including, but not limited to, any of the following:

  * Ongoing or active infection
  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * Cardiac arrhythmias
* No psychiatric illness or social situations that would limit study compliance

PRIOR CONCURRENT THERAPY:

* At least 2 weeks since prior radiation therapy or surgery and recovered
* At least 2 weeks since other prior therapy and recovered
* No concurrent antiretroviral therapy for HIV-positive patients
* No concurrent lung, liver, or mediastinal lymph node biopsies
* No other concurrent investigational agents